Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report issued to clients and investors on Saturday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $2.00 target price on shares of Aptose Biosciences in a report on Friday, January 10th.

Aptose Biosciences Stock Up 4.1 %

APTO stock opened at $0.18 on Friday. The company has a market cap of $10.59 million, a PE ratio of -0.06 and a beta of 0.87. Aptose Biosciences has a 52 week low of $0.13 and a 52 week high of $2.20. The business has a 50-day simple moving average of $0.21 and a 200 day simple moving average of $0.35.

Institutional Trading of Aptose Biosciences

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp boosted its holdings in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 401,750 shares of the biotechnology company’s stock after acquiring an additional 167,282 shares during the quarter. Sigma Planning Corp owned 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.